C
Charles D. McDermott
Researcher at University of California, San Diego
Publications - 6
Citations - 510
Charles D. McDermott is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Prinomastat & Lung cancer. The author has an hindex of 6, co-authored 6 publications receiving 503 citations.
Papers
More filters
Journal ArticleDOI
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.
David R. Shalinsky,John Brekken,H. Zou,Charles D. McDermott,Peter A. Forsyth,Dylan R. Edwards,S. Margosiak,S. Bender,G. Truitt,Alexander W. Wood,Nissi Varki,Krzysztof Appelt +11 more
TL;DR: In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance, and decreased the number of murine melanoma lesions arising in the lung in an intravenous metastasis model when given in combination with carboplatin or Taxol.
Journal Article
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
David R. Shalinsky,John Brekken,Helen Y. Zou,Laura A. Bloom,Charles D. McDermott,Scott Zook,Nissi Varki,Krzysztof Appelt +7 more
TL;DR: Treatment with this novel matrix metalloprotease inhibitor may be beneficial in advanced lung cancers and other chemoresistant malignancies, and enhanced growth inhibitions when AG3340 is used in combination with cytotoxic agents are demonstrated.
Journal ArticleDOI
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
TL;DR: Despite similar profiles of enzyme inhibition across the family of enzymes, efficacy against the Lewis lung carcinoma murine model varied from tumor growth enhancement, to significant reductions in the size of primary tumors and the number of lung metastases.
Journal ArticleDOI
Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization.
Claudio R. Garcia,Dirk-Uwe Bartsch,Maria E. Rivero,Martin Hagedorn,Charles D. McDermott,Germaine Bergeron-Lynn,Lingyun Cheng,Krzysztof Appelt,William R. Freeman +8 more
TL;DR: AG3340 administered systemically by intraperitoneal injections inhibited hypoxia-induced retinal neovascularization in an animal model and appears to be a promising candidate for the treatment of neov vascular retinal diseases.
Journal ArticleDOI
The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy.
Ugur Ozerdem,Beata Mach-Hofacre,Lingyun Cheng,Sunan Chaidhawangul,Kelly S. Keefe,Charles D. McDermott,Germaine Bergeron-Lynn,Krzysztof Appelt,William R. Freeman +8 more
TL;DR: Intravitreally administered prinomastat decreased development of PVR in an experimental model which made use of dispase to induce PVR, and Clinically significant PVR with retinal detachment developed in 76% of rabbits in the control group.